Cisen Pharmaceutical Ltd.

Primary objective: To compare the absorption rate and extent of absorption of desmopressin acetate tablets (trade name: Minirin®, strength: 0.2 mg) manufactured by Chenxin Pharmaceutical Co., Ltd. under fasting conditions, using Ferring AG-licensed desmopressin acetate tablets as the reference formulation and Chenxin Pharmaceutical Co., Ltd.'s desmopressin acetate tablets (strength: 0.2 mg) as the test formulation, and to evaluate the bioequivalence of the two formulations. Secondary objective: To observe the safety of oral administration of the test formulation desmopressin acetate tablets (strength: 0.2 mg) and the reference formulation desmopressin acetate tablets (trade name: Minirin®, strength: 0.2 mg) in healthy participants.

Primary Objective: Preliminary dose-duration-effect study: This study aimed to describe the skin response at the administration site following a single topical administration of fluticasone propionate cream (Cutivate®, 0.05% (15 g)) certified by GlaxoSmithKline (Ireland) Limited to healthy study participants, obtaining three dose durations (ED50, D1, and D2) to provide a reference for a pivotal human bioequivalence study. Pivotal In Vivo Bioequivalence Study: Using fluticasone propionate cream (0.05% (15 g)) certified by Shandong Chenxin Fodu Pharmaceutical Co., Ltd. as the test formulation and fluticasone propionate cream (Cutivate®, 0.05% (15 g)) certified by GlaxoSmithKline (Ireland) Limited as the reference formulation, the pharmacodynamic parameter skin response colorimetric values at the administration site were compared after a single topical administration of the test formulation (T) or the reference formulation (R) to evaluate the human bioequivalence of the two formulations. Secondary objective: To evaluate the safety of the test formulation and the reference formulation in participants of the Chinese Adult Health Study.

Primary objective: To evaluate the pharmacokinetics of baricitinib tablets (4 mg, developed by Chenxin Pharmaceutical Co., Ltd.) in healthy participants and assess the bioequivalence of the two formulations after oral administration in a fasting state, using baricitinib tablets (trade name: Olumiant®, 4 mg, certified by Irilyry Co., Ltd., Japan) as the test formulation. Secondary objective: To evaluate the safety of a single oral administration of the test and reference formulations of baricitinib tablets in healthy Chinese participants in a fasting state.